Results 171 to 180 of about 3,281,120 (365)

Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules

Neurobiology of Disease, 2013
Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for ...
Akihiro Mouri, Taku Nagai, Daisuke Ibi, Kiyofumi Yamada   +3 more
doaj  

Neural Correlates of Cognitive Improvement After Virtual Reality‐Based Cognitive Remediation in Psychosis and Mood Disorders: A Randomized Controlled Trial

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Cognitive impairment in mood disorders and schizophrenia spectrum disorders hampers patients' clinical and functional outcomes. A key challenge in pro‐cognitive treatment development is the limited insight into the underlying neurocircuitry correlates of cognitive changes.
Viktoria Damgaard, Andreas Elleby Jespersen, Ida Kruse Søndergaard, Anders Lumbye, Maj Vinberg, Louise Birkedal Glenthøj, Merete Nordentoft, Anjali Sankar, Gitte Moos Knudsen, Julian Macoveanu, Kamilla Woznica Miskowiak   +10 more
wiley   +1 more source

Safety and tolerability of antipsychotics: focus on amisulpride

Drug, Healthcare and Patient Safety, 2010
Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira31Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil ...
Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira   +2 more
doaj  

Cognitive and Psychomotor Processing Speed in Medication‐Naïve Individuals With First‐Episode of Psychosis: The Role of Peripheral Inflammatory Markers

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Hypothesis Deficits in processing speed (PS) and psychomotor speed (PMS) are core cognitive impairments in schizophrenia spectrum disorders, including first‐episode psychosis (FEP). Neuroinflammation has been proposed as a potential contributor to these deficits.
Ángel Yorca‐Ruiz, Carlos Martínez Asensi, Rebeca Magdaleno Herrero, Alexandre Díaz‐Pons, Víctor Ortiz‐García de la Foz, Luis Manuel Fernández Cacho, Ana Catalán Alcantara, Benedicto Crespo‐Facorro, Rosa Ayesa‐Arriola   +8 more
wiley   +1 more source

Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1

, 1997
Lorraine Jones‐Brando, James L. Buthod, L E Holland, Robert H. Yolken, E. Fuller Torrey   +4 more
openalex   +1 more source

Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents [PDF]

, 2008
Kondapalli Venkata Gowri Chandra Sekhar, Vajja Samabasiva Rao, M. Krishna   +2 more
openalex   +1 more source

Use of Antidepressants Decreased After Initiation of ADHD Treatment in Adults—A Finnish Nationwide Register Study Describing Use of ADHD and Non‐ADHD Medication in People With and Without ADHD

Acta Psychiatrica Scandinavica, EarlyView.
Use of ADHD and non‐ADHD medication in people with and without ADHD in Finland. ABSTRACT Introduction ADHD is often associated with comorbid psychiatric conditions. Differential diagnosis between other conditions and ADHD is not always clear, and patients are sometimes initially treated for another disorder instead.
Elisa Westman, Tuire Prami, Alvar Kallio, Ilona Iso‐Mustajärvi, Joel Jukka, Paavo Raittinen, Maarit J. Korhonen, Anita Puustjärvi, Sami Leppämäki   +8 more
wiley   +1 more source

Synthesis and Pharmacological Studies for New Benzotriazole and Dibenzodiazepine Derivatives as Antipsychotic Agents [PDF]

, 2009
Osama I. El‐Sabbagh, Sameh El-Nabtityt
openalex   +1 more source

Studies on impurities and degradation products in a potential antipsychotic agent, SIPI6398, using HPLC, semi-preparative LC, LC/ESI-MS and NMR Analyses [PDF]

, 2023
Ainan Zhou, Hengyi Zhu, Hao Qian, Xiaowen Chen, Jian-Qi Li   +4 more
openalex   +1 more source

Opportunities and Challenges of Population Pharmacogenomics

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou, Yoomi Park, Mahamadou D. Camara, Volker M. Lauschke   +3 more
wiley   +1 more source